1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.

A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran. 1229P A multicenter phase II study of sotigalimab (CD40 agonist) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers. Annals of Oncology. 2022 Sep 1; 33:s1111.

2022
https://researcherprofiles.org/profile/420600775

A.H. Ko, M. Noel, J. Chao, D. Sohal, M. Crow, P.E. Oberstein, A. Scott, A. McRee, C. Rocha Lima, L. Fong, B. Keenan, E. Filbert, F.J. Hsu, V. Shankaran